Global Primary Immunodeficiency Diseases Market US$ 7 Billion by 2023
The global primary immunodeficiency diseases market report estimates the market size in US$ million for 2015-2023, and forecasts growth trends over a period of 2018-2023. The market for key market segments has been estimated based on epidemiology approach considering patient diagnosis rates, patient treatment rate (IVIG/SCIG), average cost of treatment by regions. The highlights of the report include global number of PID patients, by disease (including subclasses), global number of patient population for treatment or therapy, global number of PID patients, by 15 most commonly identified PIDs by region, and by country, and PID patient’s gender and age by global comparative analysis. The global primary immunodeficiency disease (PIDD or PID or PI) market is dominated by North America and Europe, collectively accounting for major share of the market in 2016. National PID registries worldwide, increasing healthcare expenditure and government support are the major factors driving the global primary immunodeficiency diseases market during the forecast period.
Browse Primary Immunodeficiency Diseases Market by Disease Type (Antibody Deficiency – Agammaglobulinaemia, Common Variable Immune Deficiency, IgG Subclass Deficiency, SIgAD; Cellular Immunodeficiency – Ataxia Telangiectasia, DiGeorge Syndrome, Hyper IgM Syndromes, Wiskott-Aldrich Syndrome; Innate Immune Disorders – Complement Deficiencies, and Hyper IgE Syndrome) and Test Type (Blood and Prenatal Testing), and Treatment Type (Immunoglobulin Replacement Therapy, Antibiotics Therapy, Stem Cell and Gene Therapy) and Forecast 2015-2023.
The report also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends in strategic management. The major companies profiled in the report include Baxter nternational, Inc., Bio Products Laboratory, Biotest AG, CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB S.A., Octapharma AG, and others.
1. Disease Type
1.1. Antibody Deficiency
1.1.2. Common Variable Immune Deficiency
1.1.3. IgG Subclass Deficiency
1.1.4. Selective IgA Deficiency (SIgAD)
1.2. Cellular Immunodeficiency
1.2.1. Ataxia Telangiectasia
1.2.2. DiGeorge Syndrome
1.2.3. Hyper IgM Syndromes
1.2.4. Wiskott-Aldrich Syndrome
1.3. Innate Immune Disorder
1.3.1. Complement Deficiencies
1.3.2. Hyper IgE Syndrome
2. Test Type
2.1. Blood Testing
2.2. Prenatal Testing
3. Treatment Type
3.1. Immunoglobulin Replacement Therapy
3.2. Antibiotics Therapy
3.3. Stem cell and Gene Therapy
4. Geography (Region, Country)
4.1. North America (U.S., Canada)
4.2. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
4.3. Asia Pacific (Japan, China, India, Rest of APAC)
4.4. Latin America (Brazil, Mexico, Rest of LA)
4.5. Rest of the World
5. Company Profiles
5.1. Baxter International, Inc.
5.2. Bio Products Laboratory
5.3. Biotest AG
5.4. CSL Behring LLC
5.5. Grifols S.A.
5.6. Kedrion S.p.A.
5.7. LFB S.A.
5.8. Octapharma AG
To request Table of Contents and Sample Pages of this report visit:
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare IT, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Primary Immunodeficiency Diseases Market US$ 7 Billion by 2023 here
News-ID: 994213 • Views: 343
More Releases from iHealthcareAnalyst, Inc.
Global Blood Gas Monitoring Products Market Growing at CAGR of 6.2% to Reach $5. …
The global market for blood gas monitoring products is estimated to reach $5.5 billion by the end of 2025, expanding at a CAGR of 6.2% during the forecast period, supported by growing geriatric population, rising prevalence of chronic diseases, and technological advances. The global blood gas monitoring devices market research report provides market size (Revenue US$ Million 2017 to 2025), market share analysis, growth trends and forecast (CAGR%, 2019 to 2025).
Advances in Mobile Connectivity Services to Drive Telemedicine Technologies and …
According to a new market research report Telemedicine Technologies and Services Market 2015-2023 published by iHealthcareAnalyst, Inc., the global computer-aided detection market to reach US$ 73.2 Billion by 2023, expanding at a CAGR of 13.5% from 2018-2023. Visit the Global Telemedicine Technologies and Services Market Analysis and Forecast 2018-2023 report at https://www.ihealthcareanalyst.com/report/telemedicine-technologies-services-market/ The global telemedicine technologies and services market newly published (updated 2018) report estimates the market size (US$ million 2015-2023)
Global Internet Pharmacies Market to Cross US$ 100 Billion by 2023
The global internet pharmacies market is estimated to reach US$ 106 Billion by 2023, growing at a CAGR of 15.7% over the forecast period, driven by rising personal disposable income, lower prices, surge in internet penetration, stupendous growth of online retail market and a large number of online players entering the online healthcare product segment. The major players are in a race to increase their share in the industry by
Global Cerebrospinal Fluid Management Market to Reach 1.9 US$ billion by 2023 gr …
According to a new market research report (updated 2018) published by iHealthcareAnalyst, Inc., Cerebrospinal Fluid Management Market – Global CSF Products Analysis and Forecast 2018-2023, the global cerebrospinal fluid management market was valued at US$ 1,045 Million in 2013 and to reach US$ 1.9 billion by 2023, growing at a CAGR of 5.5% from 2018-2023. Visit the Global Cerebrospinal Fluid Management Market – Global Patient Solutions, System Strengthening and End Users
More Releases for Syndrome
Carcinoid Syndrome Diarrhea Treatment Market
Increasing prevalence of rare carcinoid syndrome diarrhea to boost market growth According to the National Organization for Rare Disorders (NORD), 2017, each year, only 27 individuals per million population are estimated to be diagnosed with carcinoid tumors in the U.S., amongst whom, only 10% individuals develop carcinoid syndrome. Moreover, it affects both males and females in equal number. Increasing prevalence of the disease is in turn, increasing demand for carcinoid syndrome
Carcinoid Syndrome Diarrhea Treatment Market
Carcinoid syndrome is caused by secretion of certain harmful chemicals by carcinoid tumors. Carcinoid syndrome may occur due to infection or other related diseases, and medical or surgical treatments such as anesthesia, chemotherapy, embolization, and tumor debulking. The key symptoms of the syndrome include flushing of the skin and diarrhea, rapid heartbeat, and bronchoconstriction. If remained undiagnosed, it could lead to several complications such as weight loss, electrolyte imbalance, dehydrations,
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017, provides an overview of the Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline landscape. Gorlin syndrome, also known as nevoid
Familial Chylomicronemia Syndrome Treatment Market
Familial Chylomicronemia Syndrome is a genetic condition characterized by an inability of the body to digest fats mainly triglyceride. In Familial Chylomicronemia Syndrome, the lipoprotein lipase (LPS) is not functional, which is the enzyme that breaks down chylomicrons in the blood. The most distinctive sign of Familial Chylomicronemia Syndrome is the appearance of fatty blood on the skin, mainly owing to high level of fat in the body. People with
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H1 2017
ReportsWeb.com published “Gorlin Syndrome Market” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Original Content: Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H1 2017, provides an overview of the Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline landscape. Gorlin
Global Acute Coronary Syndrome Market
The Acute Coronary Syndrome Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. Acute coronary syndrome is one of the serious medical conditions characterized by sudden and reduced flow of blood to the heart. The symptoms of acute coronary syndrome are the same